Glenmark Pharmaceuticals Limited
NSE: GLENMARK BSE: GLENMARK
NSE
1,960.90
-55.00 (-2.73%)
Prev Close
2015.9
Open Price
2011
Volume
308,805
Today Low / High
1936 / 2011
52 WK Low / High
1275.5 / 2284.8
Range
1,863 - 2,059
BSE
2,016.90
30.15 (1.52%)
Prev Close
1986.75
Open Price
2015.85
Volume
11,620
Today Low / High
1945 / 2016.9
52 WK Low / High
1274.7 / 2286.15
Range
1,916 - 2,118
The stock is currently trading on both the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE). On the NSE, the stock is priced at 1960.9 (target range: 1,863 - 2,059), reflecting a change of -55 (-2.72831%). On the BSE, it is listed at 2016.9 (target range: 1,916 - 2,118), showing a change of 30.15 (1.51755%). The stock price is currently in decline on both exchanges, signaling a downtrend. If you're considering investing in this stock, it's important to monitor the situation closely.
01 Feb
2,011.00
-1.57%
30 Jan
1,978.70
1.88%
29 Jan
2,002.40
-0.84%
28 Jan
2,011.50
-0.89%
27 Jan
1,968.40
1.59%
23 Jan
2,000.00
-1.62%
22 Jan
1,955.00
2.16%
21 Jan
1,927.00
0.75%
20 Jan
1,980.30
-2.29%
19 Jan
1,996.00
-0.31%
16 Jan
2,022.00
-1.05%
14 Jan
2,025.00
-0.68%
13 Jan
2,028.00
-0.98%
12 Jan
2,007.20
0.51%
09 Jan
2,074.00
-3.22%
08 Jan
2,122.10
-1.99%
07 Jan
2,076.00
1.79%
06 Jan
2,031.50
2.12%
05 Jan
2,071.50
-1.56%
Glenmark Pharmaceuticals Limited Graph
Glenmark Pharmaceuticals Limited Price Target Predictions: Bullish vs. Bearish Scenarios with Ranges
If you are looking for the target price for Glenmark Pharmaceuticals Limited T1, T2, T3 for both Bullish and Bearish scenarios, here it is. For Bullish: T1, T2, T3. For Bearish: T1, T2, T3. The stock current price is 1,960.90, with potential price targets ranging from T1, T2, and T3 in both directions based on market conditions.
| Scenario | Price | Target | Range |
|---|---|---|---|
| Bullish Scenario | 2,016.90 | 2,037.07 | 1,833.36 - 2,240.78 |
| 2,057.24 | 1,645.79 - 2,468.69 | ||
| 2,077.41 | 1,454.18 - 2,700.63 | ||
| Bearish Scenario | 2,016.90 | 1,996.73 | 1,797.06 - 2,196.40 |
| 1,976.56 | 1,581.25 - 2,371.87 | ||
| 1,956.39 | 1,369.48 - 2,543.31 |
Overview of Glenmark Pharmaceuticals Limited
ISIN
INE935A01035
Industry
Drug Manufacturers - Specialty & Generic
Vol.Avg
795,542
Market Cap
552,464,523,779
Last Dividend
5
Official Website
IPO Date
2002-07-01
DCF Diff
3,220.19
DCF
-1,255
Financial Ratios Every Investor Needs
Stock Dividend of GLENMARK
| Date | Label | Adj Dividend | Dividend | Record Date | Payment Date | Declaration Date |
|---|---|---|---|---|---|---|
| 2025-10-03 | October 03, 25 | 2.5 | 2.5 | 2025-10-03 | 2025-10-26 | |
| 2025-09-15 | September 15, 25 | 2.5 | 2.5 | 2025-09-15 | 2025-10-01 | |
| 2024-09-13 | September 13, 24 | 2.5 | 2.5 | 2024-09-16 | 2024-10-27 | |
| 2023-09-18 | September 18, 23 | 2.5 | 2.5 | 2023-09-18 | 2023-10-29 | |
| 2022-09-12 | September 12, 22 | 2.5 | 2.5 | 2022-09-13 | 2022-10-27 |
Annual Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | R&D Expenses | G&A Expenses | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 13,363.29 Cr | 4,525.02 Cr | 8,838.28 Cr | 0.6614 | 973.11 Cr | 3,073.57 Cr | 4,183.75 Cr | 1,047.10 Cr | 37.11 | 2,167.58 Cr | 0.0784 |
| 2024-03-31 | 12,645.38 Cr | 4,578.90 Cr | 8,066.48 Cr | 0.6379 | 1,225.83 Cr | 2,930.76 Cr | 3,394.18 Cr | -1,501.67 Cr | -67.30 | 1,829.67 Cr | -0.1188 |
| 2023-03-31 | 11,655.56 Cr | 4,410.81 Cr | 7,244.75 Cr | 0.6216 | 1,250.04 Cr | 2,656.38 Cr | 2,811.37 Cr | 297.25 Cr | -6.01 | 1,428.88 Cr | 0.0255 |
| 2022-03-31 | 12,304.90 Cr | 4,548.10 Cr | 7,756.80 Cr | 0.6304 | 1,278.71 Cr | 2,482.77 Cr | 3,560.47 Cr | 941.71 Cr | 33.37 | 1,912.44 Cr | 0.0765 |
| 2021-03-31 | 10,943.93 Cr | 3,846.96 Cr | 7,096.97 Cr | 0.6485 | 1,318.69 Cr | 2,381.61 Cr | 2,968.02 Cr | 970.04 Cr | 34.38 | 1,944.77 Cr | 0.0886 |
Annual Financials Balance Sheet
| Date | C&C Equ. | Tot. Assets | Tot. Liab. | Stock. Equity | Tot. Debt | Net Debt | Inv. | PP&E (Net) | Curr. Def. Rev. | Non-Curr. Def. Rev. | LT Invest. | Curr. Liab. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 1,705.23 Cr | 16,049.55 Cr | 7,200.48 Cr | 8,849.4410 Cr | 2,472.67 Cr | 796.96 Cr | 3,281.20 Cr | 3,861.35 Cr | 0.00 Cr | 0.00 Cr | 60.50 Cr | 5,967.0240 Cr |
| 2024-03-31 | 1,658.27 Cr | 14,358.62 Cr | 6,511.08 Cr | 7,847.9270 Cr | 1,230.93 Cr | -427.34 Cr | 2,513.05 Cr | 3,537.48 Cr | 0.00 Cr | 131.94 Cr | 795.80 Cr | 5,818.5870 Cr |
| 2023-03-31 | 1,159.20 Cr | 19,371.68 Cr | 9,532.42 Cr | 9,473.9230 Cr | 4,607.88 Cr | 3,448.68 Cr | 2,373.62 Cr | 4,221.47 Cr | 0.00 Cr | 131.85 Cr | 47.28 Cr | 5,105.0560 Cr |
| 2022-03-31 | 1,410.53 Cr | 17,083.29 Cr | 7,645.17 Cr | 9,086.6470 Cr | 3,962.02 Cr | 2,551.50 Cr | 2,499.83 Cr | 4,653.55 Cr | 0.00 Cr | 121.32 Cr | 55.66 Cr | 4,689.4310 Cr |
| 2021-03-31 | 1,138.10 Cr | 15,603.58 Cr | 8,539.30 Cr | 7,064.6270 Cr | 4,985.72 Cr | 3,847.62 Cr | 2,276.83 Cr | 4,203.54 Cr | 4.39 Cr | 136.61 Cr | 51.90 Cr | 4,201.0200 Cr |
Annual Financials Cash Flow Statement
| Date | Operating Cash | Investing Cash | Financing Cash | Free Cash | Cash Change | Cash at End | CapEx | Income | Debt Repay | Dividends | Inventory |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | -827.5950 Cr | 2.0940 Cr | 787.0450 Cr | -1,577.1640 Cr | 17.4370 Cr | 1,675.7070 Cr | -750.7200 Cr | 1,399.2090 Cr | 1,200.5120 Cr | -70.4420 Cr | -450.8070 Cr |
| 2024-03-31 | -265.4440 Cr | 4,543.7300 Cr | -3,906.1270 Cr | -1,163.8220 Cr | 215.2440 Cr | 1,658.2700 Cr | -898.3780 Cr | -1,501.6680 Cr | -3,168.3670 Cr | -117.7520 Cr | -513.8580 Cr |
| 2023-03-31 | 625.3920 Cr | -528.4910 Cr | -77.4560 Cr | 17.6290 Cr | 32.5000 Cr | 1,443.0260 Cr | -607.7630 Cr | 868.4510 Cr | 629.9690 Cr | -136.6060 Cr | -375.1690 Cr |
| 2022-03-31 | 1,108.6520 Cr | -333.2800 Cr | -520.4910 Cr | 318.5350 Cr | 272.4310 Cr | 1,410.5260 Cr | -790.1170 Cr | 1,441.2460 Cr | -1,030.7970 Cr | -92.6950 Cr | -203.4190 Cr |
| 2021-03-31 | 1,131.2130 Cr | -675.2360 Cr | -441.7790 Cr | 356.4550 Cr | 27.8200 Cr | 1,138.0950 Cr | -774.7580 Cr | 1,382.4750 Cr | 18.9670 Cr | -70.4470 Cr | -133.8080 Cr |
Quarterly Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|
| 2025-12-31 | 3,900.62 Cr | 2,290.95 Cr | 1,609.67 Cr | 0.4127 | 715.30 Cr | 403.21 Cr | 14.29 | 729.88 Cr | 0.1034 |
| 2025-09-30 | 6,046.87 Cr | 2,491.96 Cr | 3,554.91 Cr | 0.5879 | 1,628.25 Cr | 610.35 Cr | 21.63 | 1,175.06 Cr | 0.1009 |
| 2025-06-30 | 3,264.44 Cr | 1,908.26 Cr | 1,356.18 Cr | 0.4154 | 450.59 Cr | 46.87 Cr | 1.66 | 283.73 Cr | 0.0144 |
| 2025-03-31 | 3,195.72 Cr | 1,260.62 Cr | 1,935.10 Cr | 0.6055 | -433.94 Cr | 4.65 Cr | 0.16 | 440.50 Cr | 0.0015 |
| 2024-12-31 | 3,418.68 Cr | 1,084.24 Cr | 2,334.44 Cr | 0.6828 | 1,545.96 Cr | 347.96 Cr | 12.33 | 604.61 Cr | 0.1018 |
Quarterly Financials Balance Sheet
| Date | Cash & Equiv. | Short-Term Inv. | Cash & Short-Term | Net Receivables | Inventory | Total Curr. Assets | PP&E (Net) | Total Assets | Total Liabilities |
|---|---|---|---|---|---|---|---|---|---|
| 2025-09-30 | 2,646.84 Cr | 311.50 Cr | 2,958.35 Cr | 3,773.12 Cr | 3,280.72 Cr | 11,453.22 Cr | 4,094.02 Cr | 19,002.02 Cr | 9,420.40 Cr |
| 2025-06-30 | 0.00 Cr | 0.00 Cr | 1,705.23 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | -8,849.07 Cr |
| 2025-03-31 | 1,705.23 Cr | 6.35 Cr | 1,711.57 Cr | 4,181.06 Cr | 3,281.20 Cr | 9,295.47 Cr | 3,861.35 Cr | 16,049.55 Cr | 7,200.48 Cr |
| 2024-12-31 | 0.00 Cr | 0.00 Cr | 1,820.24 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | -8,445.50 Cr |
| 2024-09-30 | 1,818.90 Cr | 221.80 Cr | 2,040.70 Cr | 2,863.43 Cr | 2,840.21 Cr | 9,033.48 Cr | 3,550.22 Cr | 15,235.34 Cr | 6,789.85 Cr |
Quarterly Financials Cash Flow Statement
| Date | Net Income | Operating Cash Flow | Investing Cash Flow | Financing Cash Flow | Net Cash Change | Cash at End | Cash at Beginning | CapEx | Free Cash Flow |
|---|---|---|---|---|---|---|---|---|---|
| 2025-06-30 | 46.87 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2025-03-31 | 4.65 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-12-31 | 347.96 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-09-30 | 354.21 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-06-30 | 340.27 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
Splits History
| Date | Label | Split Ratio |
|---|---|---|
| 2007-09-10 | September 10, 07 | 2:1 |
| 2005-03-04 | March 04, 05 | 2:1 |
| 2003-10-23 | October 23, 03 | 5:1 |
Similar Stocks: Drug Manufacturers - Specialty & Generic
| Company Name | Symbol | Price | Market Cap | Volume |
|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | SUNPHARMA | ₹1,595.30 | ₹3,827,659,077,641.00 | ₹1,849,710.00 |
| Divi's Laboratories Limited | DIVISLAB | ₹6,031.00 | ₹1,601,041,005,980.00 | ₹96,030.00 |
| Torrent Pharmaceuticals Limited | TORNTPHARM | ₹3,960.80 | ₹1,340,514,698,752.00 | ₹50,076.00 |
| Dr. Reddy's Laboratories Limited | DRREDDY | ₹1,200.00 | ₹999,081,828,000.00 | ₹380,220.00 |
| Lupin Limited | LUPIN | ₹2,152.80 | ₹983,396,887,200.00 | ₹153,290.00 |
| Zydus Lifesciences Limited | ZYDUSLIFE | ₹885.30 | ₹890,818,951,347.00 | ₹140,316.00 |
| Mankind Pharma Limited | MANKIND | ₹2,124.00 | ₹876,797,972,928.00 | ₹287,261.00 |
| Aurobindo Pharma Limited | AUROPHARMA | ₹1,182.80 | ₹686,972,159,684.00 | ₹574,635.00 |
| Alkem Laboratories Limited | ALKEM | ₹5,620.00 | ₹671,955,300,000.00 | ₹20,830.00 |
| Glenmark Pharmaceuticals Limited | GLENMARK | ₹1,960.90 | ₹553,367,566,368.00 | ₹308,665.00 |
| Laurus Labs Limited | LAURUSLABS | ₹940.90 | ₹507,951,058,004.00 | ₹1,196,464.00 |
| Suven Pharmaceuticals Limited | SUVENPHAR | ₹1,078.00 | ₹412,407,234,624.00 | ₹1,177,218.00 |
| Ipca Laboratories Limited | IPCALAB | ₹1,427.70 | ₹362,213,512,039.00 | ₹38,416.00 |
| Ajanta Pharma Limited | AJANTPHARM | ₹2,782.00 | ₹347,570,905,968.00 | ₹27,274.00 |
| J. B. Chemicals & Pharmaceuticals Limited | JBCHEPHARM | ₹1,880.70 | ₹301,730,104,500.00 | ₹48,837.00 |
| Emcure Pharmaceuticals Ltd. | EMCURE | ₹1,485.00 | ₹281,515,221,900.00 | ₹56,011.00 |
| Piramal Enterprises Limited | PEL | ₹1,124.20 | ₹254,856,250,172.00 | ₹2,148,582.00 |
| Wockhardt Limited | WOCKPHARMA | ₹1,382.20 | ₹224,596,675,992.00 | ₹241,327.00 |
| AstraZeneca Pharma India Limited | ASTRAZEN | ₹8,615.00 | ₹215,375,000,000.00 | ₹3,296.00 |
| Eris Lifesciences Limited | ERIS | ₹1,386.10 | ₹188,810,232,615.00 | ₹11,485.00 |
| Neuland Laboratories Limited | NEULANDLAB | ₹13,251.00 | ₹170,008,859,139.00 | ₹53,893.00 |
| Alembic Pharmaceuticals Limited | APLLTD | ₹777.60 | ₹152,847,485,222.00 | ₹26,375.00 |
| Jubilant Pharmova Limited | JUBLPHARMA | ₹953.75 | ₹151,045,147,155.00 | ₹22,670.00 |
| NATCO Pharma Limited | NATCOPHARM | ₹835.90 | ₹149,717,940,333.00 | ₹208,764.00 |
| Cohance Lifesciences Limited | COHANCE | ₹367.50 | ₹140,593,423,950.00 | ₹169,039.00 |
| Caplin Point Laboratories Limited | CAPLIPOINT | ₹1,802.10 | ₹136,980,677,362.00 | ₹25,851.00 |
| Granules India Limited | GRANULES | ₹557.20 | ₹135,215,008,555.00 | ₹273,857.00 |
| Glenmark Life Sciences Limited | GLS | ₹1,086.00 | ₹133,070,838,000.00 | ₹130,938.00 |
| Alivus Life Sciences Ltd. | ALIVUS | ₹937.60 | ₹115,025,705,600.00 | ₹28,984.00 |
| Viyash Scientific Limited | VIYASH | ₹203.61 | ₹88,815,813,868.00 | ₹245,657.00 |
| Procter & Gamble Health Limited | PGHL | ₹5,303.00 | ₹88,026,522,746.00 | ₹4,739.00 |
| Strides Pharma Science Limited | STAR | ₹877.00 | ₹80,835,470,178.00 | ₹379,638.00 |
| Aarti Pharmalabs Limited | AARTIPHARM | ₹756.05 | ₹68,533,886,629.00 | ₹69,500.00 |
| Akums Drugs & Pharmaceuticals Ltd. | AKUMS | ₹446.00 | ₹68,283,517,868.00 | ₹92,422.00 |
| FDC Limited | FDC | ₹376.70 | ₹61,330,558,643.00 | ₹31,298.00 |
| Shilpa Medicare Limited | SHILPAMED | ₹288.95 | ₹56,513,365,733.00 | ₹4,776,413.00 |
| Sequent Scientific Limited | SEQUENT | ₹202.40 | ₹50,564,340,966.00 | ₹13,647.00 |
| Sun Pharma Advanced Research Company Limited | SPARC | ₹126.08 | ₹40,915,681,815.00 | ₹7,990,855.00 |
| Innova Captab Limited | INNOVACAP | ₹695.00 | ₹39,771,325,655.00 | ₹12,945.00 |
| Gujarat Themis Biosyn Ltd. | GUJTHEM | ₹326.85 | ₹35,615,296,865.00 | ₹58,760.00 |
| Aarti Drugs Limited | AARTIDRUGS | ₹386.75 | ₹35,298,672,500.00 | ₹63,468.00 |
| Orchid Pharma Limited | ORCHPHARMA | ₹693.00 | ₹35,148,339,765.00 | ₹14,366.00 |
| RPG Life Sciences Limited | RPGLIFE | ₹2,007.90 | ₹33,208,688,219.00 | ₹3,827.00 |
| Gufic Biosciences Limited | GUFICBIO | ₹303.90 | ₹30,475,853,573.00 | ₹29,080.00 |
| Suven Life Sciences Limited | SUVEN | ₹132.81 | ₹30,210,821,940.00 | ₹346,948.00 |
Key Executives
President and Chief Human Resources Officer
Alind Sharma
Gender: male
Year Born: 1971
President & Business Head of India Formulations
Alok Malik
Gender: male
Year Born:
President & Chief Quality Officer
Brijlal Motwani
Gender: male
Year Born:
President & Chief Quality Officer
Indrajit Bose
Gender: male
Year Born:
President and Business Head of Europe & Emerging Markets
Christoph Stoller
Gender: male
Year Born:
Chairman, MD & Chief Executive Officer
Glenn Mario Saldanha
Gender: male
Year Born: 1970
Company Secretary & Compliance Officer
Harish Vinayak Kuber
Gender: male
Year Born:
President & Business Head of North America
Marc T. Kikuchi
Gender: male
Year Born: 1969
President & Head of Global Pharmaceutical Development
Ulhas R. Dhuppad
Gender: male
Year Born: 1967
Executive Director of Corporate Services & Executive Director
Cherylann Maria Pinto
Gender: female
Year Born: 1967
FAQs about Glenmark Pharmaceuticals Limited
Who is the CEO of the company?
The CEO is Glenn Mario Saldanha.
What is the current market price of the stock?
The current price is ₹1,957.70.
What is the 52-week price range?
The range is ₹1275.5-2284.8.
What is the market capitalization of the company?
The market capitalization is ₹55,246.45 crores.
What is the dividend yield?
The dividend yield is 0.26%.
What is the Price-to-Earnings (P/E) ratio?
The P/E ratio is 51.87.
Which sector does the company belong to?
The company operates in the Healthcare sector.
What does the company do?
Overview of Glenmark Pharmaceuticals Limited (ISIN: INE935A01035) is a leading Drug Manufacturers - Specialty & Generic in India. With a market capitalization of ₹55,246.45 crores and an average daily volume of 795,542 shares, it operates in the Drug Manufacturers - Specialty & Generic. The company last declared a dividend of ₹5.